{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["alectinib"],["brigatinib"],["lorlatinib"]],"indication":"previously treated ALK-positive stage IV non-squamous NSCLC","name":"NCI-NRG ALK Protocol","nct_id":"NCT03737994","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nci-nrg-alk-protocol-nct03737994. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients with ALK L1198F mutation (alone or in combination with another ALK mutation) receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"ALK L1198F mutation (alone or combination with ALK inhibitor)","type":"EXPERIMENTAL"},{"description":"Patients with Cy1156Y mutation receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"C1156Y","type":"EXPERIMENTAL"},{"description":"Patients with a compound mutation receive lorlatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"Compound mutation","type":"EXPERIMENTAL"},{"description":"Patients with F1174 receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"F1174","type":"EXPERIMENTAL"},{"description":"Patients with G1202 (including G1202del and G1202R) receive either lorlatinib PO QD or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"G1202 (including G1202del and G1202R)","type":"EXPERIMENTAL"},{"description":"Patients with I1171 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"I1171","type":"EXPERIMENTAL"},{"description":"Patients with L1196 (including L1196M) mutation receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, or ensartinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"L1196 (including L1196M)","type":"EXPERIMENTAL"},{"description":"Patients with MET amplification receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"MET amplification","type":"EXPERIMENTAL"},{"description":"Patients with no ALK-resistant mutations receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, ensartinib PO QD, or pemetrexed IV over 10 minutes on day 1 with or without either cisplatin IV or carboplatin IV on day 1. ALK inhibitor cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Pemetrexed-based treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Maintenance treatment of pemetrexed may continue until disease progression or unacceptable toxicity.","label":"No ALK-resistance mutations","type":"EXPERIMENTAL"},{"description":"Patients with V1180 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"V1180","type":"EXPERIMENTAL"}],"collaborators":["NRG Oncology"],"completion_date":{"date":"2026-03-17","type":"ACTUAL"},"conditions":["Lung Non-Squamous Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":{"count":10,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Alectinib","otherNames":["AF 802","AF-802","AF802","Alecensa","ALK Inhibitor RO5424802","CH 5424802","CH-5424802","CH5424802","RG 7853","RG-7853","RG7853","RO 5424802","RO-5424802","RO5424802"],"type":"DRUG"},{"name":"Brigatinib","otherNames":["Alunbrig","AP 26113","AP-26113","AP26113","Biganib","Briganix","Trepmac"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","JM8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Ceritinib","otherNames":["LDK 378","LDK-378","LDK378","Zykadia"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"],"type":"DRUG"},{"name":"Crizotinib","otherNames":["Alkixen","Crizocent","MET Tyrosine Kinase Inhibitor PF-02341066","PF 02341066","PF-02341066","PF-2341066","PF02341066","Xalkori"],"type":"DRUG"},{"name":"Ensartinib","otherNames":["X 396","X-396","X396"],"type":"DRUG"},{"name":"Lorlatinib","otherNames":["2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-","Lorbrena","Lorviqua","PF 06463922","PF-06463922","PF06463922"],"type":"DRUG"},{"name":"Pemetrexed","otherNames":["MTA","Multitargeted Antifolate","Pemfexy"],"type":"DRUG"}],"last_update":"2026-04-23","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-07-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria","timeFrame":"Baseline to 24 weeks"}],"references":[],"start_date":{"date":"2019-07-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03737994"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nci-nrg-alk-protocol-nct03737994"}